Neurol. praxi. 2020;21(2):104-108 | DOI: 10.36290/neu.2019.061
Ocrelizumab and novel therapeutic goals in multiple sclerosis
- Neurologické oddělení Nemocnice Jihlava
The group of drugs intended for the treatment of multiple sclerosis has continuously expanded to include new agents in the recent years. The first drug intended not only for the treatment of relapsing-remitting, but also primary-progressive multiple sclerosis is the monoclonal antibody ocrelizumab. The increasing number of effective drugs simultaneously expands treatment algorithm options. Disease stability remains the therapeutic goal; however, its definition has shifted from a mere monitoring of clinical signs and symptoms of disease relapse or progression to more complex composite parameters encompassing activity or progression of multiple sclerosis that cannot be detected with routine clinical examination. Other parameters observed include magnetic resonance imaging activity and changes in gait speed and upper limb dexterity. Implementation of the above parameters into clinical trials allows for a more detailed comparison of efficacy of individual drugs, leading to a consideration of incorporating the above-mentioned tests into routine clinical practice.
Keywords: multiple sclerosis, ocrelizumab, EDSS, NEDA, NEPAD, PIRA.
Received: August 16, 2019; Accepted: August 22, 2019; Prepublished online: August 22, 2019; Published: June 2, 2020 Show citation
References
- Bakshi R, Minagar A, Jaisani Z, Wolinsky JS. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx 2005; 2: 277-303.
Go to original source... 
Go to PubMed... - Bjartmar C, Fox RJ. Pathological mehanisms and disease progression of multiple sclerosis: therapeutic implications. Drugs Today 2002; 38(1): 17. Go to original source... Go to PubMed...
- Coyle PK, Reder AT, Freedman MS, Fang J, Dangond F. Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon ?-1a in the EVIDENCE study. Journal of the Neurological Sciences 2017; 379: 151-156. Go to original source... Go to PubMed...
- De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, Gasperini C. Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study. Journal of the Neurological Sciences 2012; 312: 97-101. Go to original source... Go to PubMed...
- De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BM, Hennessy B, Casset-Semanaz F, Lehr L, Stubinski B, Jack DL, Barkhof F. Efficacy of subcutaneous interferon ?-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2014; 85: 647-653. Go to original source... Go to PubMed...
- Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Pol-man CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254-260. Go to original source... Go to PubMed...
- Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006; 67(6): 944-953. Go to original source... Go to PubMed...
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302. Go to original source... Go to PubMed...
- Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Malhotra A, Newsome SD, Oh J, Reich DS, Richert N, Rammohan K, Khan O, Radue EW, Ford C, Halper J, Li D. Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. AJNR Am J Neuroradiol. 2016; 37(3): 394-401. doi: 10.3174/ajnr.A4539. Epub 2015 Nov 12. Go to original source... Go to PubMed...
- Varosanec M, Uher T, Horakova D, Hagemeier J, Bergsland XN, Tyblova M, Seidl Z, Vaneckova M, Krasensky J, Dwyer MG, Havrdova E, Zivadinov R. Longitudinal mixed-effect model analysis of the association between global and tissue-specific brain atrophy and lesion accumulation in patients with clinically isolated syndrome. AJNR Am J Neuroradiol 2015; 36: 1457-1464. Go to original source... Go to PubMed...
- Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci. 2007; 256(Suppl. 1): S5-13. Epub 2007 Mar 7. Go to original source... Go to PubMed...